大洋生物
(003017)
| 流通市值：17.33亿 | | | 总市值：21.05亿 |
| 流通股本：6915.85万 | | | 总股本：8400.00万 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 248,970,295.2 | 909,955,718.12 | 671,793,437.23 | 437,218,490.66 |
| 营业收入 | 248,970,295.2 | 909,955,718.12 | 671,793,437.23 | 437,218,490.66 |
| 二、营业总成本 | 222,247,645.62 | 844,689,203.2 | 627,413,288.28 | 411,703,996.76 |
| 营业成本 | 191,316,962.53 | 732,057,470.06 | 543,822,330.86 | 354,045,560.45 |
| 税金及附加 | 1,798,408.24 | 7,630,063.11 | 5,428,926.86 | 3,391,735 |
| 销售费用 | 2,744,277.15 | 9,791,201.44 | 6,320,965.07 | 4,401,790.49 |
| 管理费用 | 18,878,286.16 | 69,552,319.18 | 50,424,929.96 | 34,626,169.62 |
| 研发费用 | 8,948,093.95 | 28,783,859.27 | 21,497,467.73 | 16,202,347.62 |
| 财务费用 | -1,438,382.41 | -3,125,709.86 | -81,332.2 | -963,606.42 |
| 其中:利息费用 | 988,783.3 | 6,767,211.56 | 5,655,270.63 | 4,076,426.12 |
| 其中:利息收入 | 2,140,265.22 | 8,847,913.71 | 6,410,104.08 | 4,330,358.07 |
| 加:公允价值变动收益 | -371,617.8 | 1,472,424.84 | 248,005.48 | - |
| 加:投资收益 | -326,255.33 | -1,107,900.51 | -1,349,951.13 | -658,994.75 |
| 资产处置收益 | - | 85,131.93 | 3,841 | 3,841 |
| 资产减值损失(新) | 496,883.9 | -7,014,898.62 | -1,815,049.9 | -1,683,659.41 |
| 信用减值损失(新) | -1,520,197.75 | -1,942,840.05 | -1,732,639.48 | -1,648,530 |
| 其他收益 | 7,829,147.85 | 18,609,088.59 | 14,664,442.69 | 8,037,343.26 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 32,830,610.45 | 75,367,521.1 | 54,398,797.61 | 29,564,494 |
| 加:营业外收入 | 26,149.12 | 388,496.97 | 101,882.79 | 65,611.27 |
| 减:营业外支出 | 1,920,082.03 | 4,113,278.3 | 324,449.35 | 53,584.47 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 30,936,677.54 | 71,642,739.77 | 54,176,231.05 | 29,576,520.8 |
| 减:所得税费用 | 1,607,729.53 | 7,907,228.56 | 2,910,453.65 | -1,859,797 |
| 六、净利润 | 29,328,948.01 | 63,735,511.21 | 51,265,777.4 | 31,436,317.8 |
| 持续经营净利润 | 29,328,948.01 | 63,735,511.21 | 51,265,777.4 | 31,436,317.8 |
| 归属于母公司股东的净利润 | 29,343,179.68 | 63,746,331.5 | 51,265,777.4 | 31,436,317.8 |
| 少数股东损益 | -14,231.67 | -10,820.29 | - | - |
| (一)基本每股收益 | 0.36 | 0.78 | 0.62 | 0.39 |
| (二)稀释每股收益 | 0.36 | 0.78 | 0.62 | 0.39 |
| 九、综合收益总额 | 29,328,948.01 | 63,735,511.21 | 51,265,777.4 | 31,436,317.8 |
| 归属于母公司股东的综合收益总额 | 29,343,179.68 | 63,746,331.5 | 51,265,777.4 | 31,436,317.8 |
| 归属于少数股东的综合收益总额 | -14,231.67 | -10,820.29 | - | - |
| 公告日期 | 2025-04-22 | 2025-04-22 | 2024-10-19 | 2024-08-27 |
| 审计意见(境内) | | 标准无保留意见 | | |